

US009254380B2

(12) United States Patent Ameri et al.

(10) Patent No.:

US 9,254,380 B2

(45) **Date of Patent:**

Feb. 9, 2016

(54) MRI COMPATIBLE TACHYCARDIA LEAD

(75) Inventors: **Masoud Ameri**, Maple Plain, MN (US);

Yingbo Li, Woodbury, MN (US)

(73) Assignee: Cardiac Pacemakers, Inc., St. Paul,

MN (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 612 days.

(21) Appl. No.: 12/880,703

(22) Filed: Sep. 13, 2010

(65) **Prior Publication Data**

US 2011/0093054 A1 Apr. 21, 2011

Related U.S. Application Data

(60) Provisional application No. 61/252,915, filed on Oct. 19, 2009.

(51)	Int.	C1
UDI.	, m.	CI.

 A61N 1/05
 (2006.01)

 A61N 1/375
 (2006.01)

 A61N 1/08
 (2006.01)

(52) U.S. Cl.

(58) Field of Classification Search

CPC A61N 1/056; A61N 1/05; A61N 1/3752; A61N 1/0563; A61N 2001/086
USPC 607/2, 9, 116, 119, 122
See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

3,614,692 A 10/1971 Rozelle et al. 4,131,759 A 12/1978 Felkel

4,135,518 A 4,146,036 A 4,209,019 A 4,253,462 A 4,350,169 A 4,381,013 A 4,404,125 A	6/1980 3/1981 9/1982 4/1983	Dutcher Dutcher et al. Dutcher et al. Dutcher et al. Dutcher et al. Dutcher Abolins et al.	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(Continued)		

FOREIGN PATENT DOCUMENTS

CN 1762510 A 4/2006 CN 1905789 A 1/2007 (Continued)

OTHER PUBLICATIONS

International Search Report and Written Opinion issued in PCT/US2012/055673, mailed Dec. 13, 2012, 10 pages.

International Search Report and Written Opinion issued in PCT/US2009/038629, mailed Jun. 29, 2009, 11 pages.

Gray, Robert W. et al., "Simple design changes to wires to substantially reduce MRI-induced heating at 1.5 T: implications for implanted leads", Magnetic Resonance Imaging 23 (2005) 887-891.

(Continued)


Primary Examiner — Christopher D Koharski
Assistant Examiner — Pamela M Bays

(74) Attorney, Agent, or Firm — Faegre Baker Daniels LLP

(57) ABSTRACT

A medical device lead includes a proximal connector configured to couple the lead to a pulse generator, an insulative lead body extending distally from the proximal connector, and a conductor assembly extending distally from the proximal connector within the lead body. The conductor assembly includes a conductor having a proximal end electrically coupled to the connector and a distal end electrically coupled to a defibrillation coil. A first portion of the defibrillation coil is exposed at an outer surface of the medical device lead and a second portion of the defibrillation coil is insulated at the outer surface of the medical device lead.

6 Claims, 4 Drawing Sheets



US 9,254,380 B2 Page 2

U.S. PATENT DOCUMENTS 6.249,708 Bl 72001 Heller at 4437,474 A 4461,436 A 411948 MacKielle et al. 4261,436 A 4274,800 A	(56)	Referen	nces Cited	6,208,881			Champeau
4,437,474	U.S.	PATENT	DOCUMENTS	6,256,541	B1	7/2001	Heil et al.
4,493,596	4 427 474 4	2/1094	Page Travertan				
4,473,480 A 1,1985 Crawford et al. G-304,784 Bi 1,12001 Allec et al. 4,674,202 A 2,1987 Roche G-360,122 Bi 3,2002 Ley et al. 4,642,032 A 2,1987 Labbe G-609,923 Bi 2,2002 Ley et al. 4,642,033 A 2,1987 Labbe G-609,923 Bi 2,2002 Ley et al. 4,642,033 A 2,1987 Labbe G-609,923 Bi 2,2002 Borgersen et al. 4,642,033 Bi 2,002 Ley et al. 4,642,034 L							
4,643,203		1/1985	Crawford et al.				
4.643,203 A 2.1987 Jabbe 6.400,902 BI 6.2002 Borgersen et al. 4.649,378 A 3.1987 Gullat et al. 4.649,378 A 3.1987 Gullat et al. 5.002,054 A 1999 Berhelsen et al. 5.002,054 A 1999 Berhelsen et al. 5.002,054 A 6.1999 Berhelsen et al. 5.002,054 B 11,2002 Slokes 5.002,054 A 6.1999 Berhelsen et al. 5.002,054 B 11,2002 Slokes 5.002,054 A 6.1999 Berhelsen et al. 5.002,054 B 11,2002 Slokes 5.002,054 B 11,2002 Bloke et al. 5.002,054 B 11,2002 Slokes 5.002,05							
4609.038							
4,869,970 A 91,989 Gulla et al. 6,494,330 52 82,002 Stigner et al.	4,649,938 A			6,428,537	B1	8/2002	Swanson et al.
Soil	4,869,970 A						
South Sout							
Sop6.516						12/2002	Honeck et al.
Sil44966 A 9/1992 Mehra et al. 6,516,239 B2 22003 Williams et al. 5,201,865 4,41993 Suchn 6,526,321 B1 5,2003 Globarer at al. 5,221,710 A 6/1993 Tstift et al. 6,654,107 B1 5,2003 Globarer at al. 5,221,3196 A 8/1993 Patrick et al. 6,671,541 B2 2,2003 Globarer at al. 5,221,3196 A 8/1993 Patrick et al. 6,721,600 B2 3,2004 Schell S,241,957 A 9/1993 Dow et al. 6,721,600 B2 3,2004 Schell S,243,951 A 9/1993 Dow et al. 6,721,600 B1 4,2004 Robinson et al. 5,226,300 A 11/1993 Li 6,813,521 B2 11/2004 Robinson et al. 5,200,300 A 4/1994 Williams et al. 6,854,803 B2 11/2004 Bischoff et al. 6,854,803 B2 2,2005 Sienez et al. 5,300,108 A 4/1994 Kreyenhagen 6,966,256 B1 2,2005 Williams S,330,522 A 7/1994 Kreyenhagen 6,966,256 B1 2,2005 Williams S,330,523 A 7/1994 Limberg et al. 6,920,361 B2 7,2005 Williams S,330,323 A 1/1994 Hammerslag et al. 6,920,361 B2 7,2005 Williams S,330,323 A 5,203,300 Windler 6,940,348 B2 9,2005 Gray et al. 6,944,489 B2 9,2005 Gray et al. 6,943,489 B2 9,2005 Gray et							
S.201.865 A 4/1993 Kuehn 6,526,321 B1 2/2003 Soher et al.							
S.217.010 A 6.1993 Tatific et al. 6.504.107 B1 5.2003 Globar et al. 5.221.996 A 8.1993 Patrick et al. 6.671.554 B2 2.2005 Globar et al. 5.231.997 A 9.1993 Camp et al. 6.721.600 B2 3.2004 Jorgenson et al. 5.241.997 A 9.1993 Dow et al. 6.721.604 B1 4.2004 Jorgenson et al. 5.246.944 A 9.1993 Dow et al. 6.813.251 B1 11.2004 Garney et al. 5.203.01.08 A 4.1994 Williams et al. 6.831.325 B1 11.2004 Garney et al. 5.304.108 A 4.1994 Girll, Jr. et al. 6.805.803 B1 2.2005 Siein et al. 5.304.108 A 4.1994 Kreyenhagen 6.866.044 B2 2.2005 Siein et al. 5.304.232 A 6.1994 Girll, Jr. et al. 6.805.803 B1 6.2005 Wang 5.370.666 A 121994 Lindberge et al. 6.900.236 B1 6.2005 Wang 5.370.666 A 121994 Lindberge et al. 6.920.361 B2 7.2005 Williams 5.387.199 A 2.1995 Siman et al. 6.944.489 B2 9.2005 Caliglemaker et al. 6.944.489 B2 9.2005 Caliglemaker et al. 6.944.489 B2 9.2005 Caliglemaker et al. 6.944.489 B2 2.2005 Gray et al. 6.936.737 B2 1.2006 Caliglemaker et al. 6.							
S.231.996 A S1993 Bardy et al.							
S.241.957 A							
S-243.911 A 9/1993 Dow'et al. 6,721.604 B1 4/2004 Robinson et al. 5,246.014 A 9/1993 Williams et al. 6,813.251 B1 1/2004 Bischoff et al. 5,259.395 A 1/1993 Li 6,813.521 B2 1/12004 Bischoff et al. 5,300.108 A 4/1994 Rebell et al. 6,859.080 B1 2/2005 Mimerez et al. 5,300.252 A 7/1994 Kreyenhagen 6,866.044 B2 2/2005 Mimerez et al. 5,330.252 A 7/1994 Kreyenhagen 6,866.044 B2 2/2005 Mimerez et al. 5,330.252 A 7/1994 Kreyenhagen 6,966.046 B2 7/2005 Williams 5,378.234 A 1/1995 Hammerslag et al. 6,920.361 B2 7/2005 Williams 5,378.234 A 1/1995 Hammerslag et al. 6,923.31 B1 8/2005 Salys Salys 5,387.79 A 2/1995 Siman et al. 6,944.489 B2 9/2005 Seligemaker et al. 5,475.553 A 6/1995 Doan 6,978.185 B2 1/2006 Cadieux et al. 6,985.775 B2 1/2006 Cadieux et al. 6,985.775 B2 1/2006 Cadieux et al. 6,993.818 B2 2/2005 Salys Cadieux et al. 6,993.818 B2 2/2005 Cadieux et al. 6,993.818 B2 2/2005 Cadieux et al. 6,993.818 B2 2/2005 Cadieux et al. 6,993.818 B2 2/2006 Cadieux et al. 6,993.818 B2 2/20						4/2004	Jorgenson et al.
5,246,014 A 9/1993 Williams et al. 6,813,521 Bi 1/2004 Gamey et al. 5,293,935 A 1/1993 Li 6,813,521 Bi 1/2004 Simbs(off et al. 5,304,332 A 6/1994 Grill, Ir. et al. 6,856,949 Bi 2/2005 Simbs(off et al. 5,324,332 A 6/1994 Grill, Ir. et al. 6,856,044 Bi 2/2005 Simbs 5,378,052 A 1/1994 Simits 6,906,256 Bi 6/2005 Warg 5,370,666 A 12/1994 Lindburg et al. 6,925,334 Bi 8/2005 Salvy & 9,377,066 A 12/1994 Lindburg et al. 6,925,334 Bi 8/2005 Salvy & 9,378,199 A 1/1995 Siman et al. 6,944,489 Bi 2/2005 Salvy & 9,378,199 A 1/1995 Siman et al. 6,944,489 Bi 2/2005 Salvy & 9,425,755 A 6/1995 Siman et al. 6,944,889 Bi 2/2005 Salvy & 1/2006 Carlow & 1/2005 Grille 6,988,755 Bi 1/2006 Carlow & 1/2005 Grille 6,998,775 Bi 1/2006 Gri				6,721,604	В1	4/2004	Robinson et al.
S.300,108 A 41094 Rebell et al. 6.850,803 Bl 22005 Jimenez et al.	5,246,014 A						
S.324.22 A							
5,330,522 A 7/1994 Smts 6,866,044 B2 32,005 Wang 3,200 Smrdy et al. 6,906,256 B1 2,000 Wang 5,370,666 A 12/1994 Lindberg et al. 6,920,361 B2 7,2005 Williams 5,378,234 A 1/1995 Hammerslag et al. 6,925,343 B1 8200 Salys 5,378,219 A 2/1995 Winkler 6,944,489 B2 9,2005 Salys 5,378,219 A 2/1995 Winkler 6,949,299 B2 9,2005 Salys 6,378,175 B2 1,2006 Smay et al. 6,948,755 B2 1,2006 Smay et al. 6,978,185 B2 1,2006 Smay et al. 6,978,185 B2 1,2006 Carleux et al. 6,985,755 B2 1,2006 Carleux et al. 6,993,318 B2 1,2006 Carleux et al. 6,993,318 B2 1,2006 Carleux et al. 6,993,318 B2 2,2006 Slevenson et al.				, ,			
Signormonia Gircon Girco							
1.1995 Hammerslag et al. 6,925,334 Bl 8,2005 Salys		10/1994	Smits	, ,			
5.387,109 A 21/995 Siman et al. 6.944,489 B2 92,0005 Gray et al.	, ,						
SA17,208 A 5/1995 Winkler 6,949,979 B2 97,005 Carly et al.	5,387,199 A			6,944,489	B2	9/2005	Zeijlemaker et al.
Section	5,417,208 A						
5,476,488 A 12/1995 Weinberg et al. 6,938,775 B2 1/2006 Reinke et al. 5,483,022 A 1/1996 Hoff 6,993,373 B2 1/2006 Vrijheid et al. 5,522,875 A 6/1996 Hoff 6,999,818 B2 2/2006 Stevenson et al. 5,534,181 A 7/1997 Waltstrand et al. 7,013,180 B2 3/2006 Dublin et al. 5,545,250 A 8/1996 Sehulte et al. 7,047,075 B2 3/2006 Krishnan 5,545,250 A 8/1996 Sehulte et al. 7,047,078 B2 5/2006 Krishnan 5,543,646 A 8/1996 Sehulte et al. 7,058,85 B2 5/2006 Culimaker et al. 5,554,294 A 1/1996 Urighte al. 7,058,85 B2 5/2006 Culimaker et al. 5,554,393 A 9/1996 Okajima 7,058,85 B2 5/2006 Krijmakr et al. 5,554,394 A 1/1996 Lindsay 7,123,913 B2 9/2006 Silvestri et al. 5,554,524 A 1/1996 Chindsay 7,123,201 B2 9/2006 Silvestri et al. 5,618,280 A 4/1997 Crouse et al. 7,138,582 B2 11/2006 Crouse et al. <							
5,483,022 A 1/1996 Mar 6,999,318 Bz 2/2006 Vriphed et al. 5,522,875 A 6/1996 Gates et al. 6,999,818 Bz 2/2006 Jenney et al. 5,522,875 A 6/1996 Gates et al. 7,013,148 Bg 2/2006 Jenney et al. 5,542,173 A 8/1996 Mar 7,013,148 Bg 3/2006 Dublin et al. 5,545,205 A 8/1996 Mar 7,013,148 Bg 3/2006 Dublin et al. 5,545,205 A 8/1996 Schulte et al. 7,047,078 Bz 5/2006 Stubbs 5,543,205 A 8/1996 Atz et al. 7,047,078 Bz 5/2006 Stubbs 5,543,205 A 8/1996 Atz et al. 7,047,078 Bz 5/2006 Stubbs 5,543,205 A 8/1996 Atz et al. 7,047,078 Bz 5/2006 Stubbs 5,543,205 A 1/1996 Lindsay 7,113,827 Bz 2/2006 Stivestri et al. 5,574,249 A 1/1/1996 Shoberg et al. 7,123,013 Bz 1/0/2006 Gray 5,584,873 A 1/1997 Opolski 7,123,013 Bz 1/1/2006 Gray 5,680,962 A 3/1997 Soukup et al. 7,138,27 Bz 1/1/2006 Gray 5,581,380 A 4/1997 Crouse et al. 7,138,28 Bz 1/1/2006 Gray							
Signature Sign							
5,534,018 A 7/1996 Wahlstrand et al. 7,013,188 B2 3/2006 Sublin et al. 5,542,173 A 8/1996 Mar et al. 7,013,182 B1 3/2006 Krishnan 5,542,205 A 8/1996 Katz et al. 7,047,075 B2 5/2006 Stubbs 5,549,646 A 8/1996 Katz et al. 7,047,078 B2 5/2006 Gunderson et al. 5,554,139 A 9/1996 Okajima 7,058,855 B2 5/2006 Gunderson et al. 5,574,249 A 11/1996 Lindsay 7,113,827 B2 9/2006 Silvestri et al. 5,595,76 A 2/1997 Opolski 7,127,294 B1 10/2006 Gray 5,609,622 A 3/1997 Soukup et al. 7,135,597 B2 11/2006 Gisselberg et al. 5,649,974 A* 7/1997 Nelson et al. 607/122 7,158,837 B2 11/2006 Usesar et al. 5,727,552 A 3/1998 Saad 7,174,220 B1 2/2007 Chitre et al. 5,728,149 A 3/1998 Laske et al. 7,205,768 B2 2/2007 Chitre et al. 5,755,742 A 5/1998 Scheulèe et al. 7,239,916 B2 2/2007 Chitre et al. 5,760,341 A 6/1998 Laske et al. 7,239,916 B2 1/2007 Chitre et al. 5,810,887 A 9							
5,542,173 A 8/1996 Mar et al. 7,043,075 B2 5/2006 Skrishnan 5,545,205 A 8/1996 Schulte et al. 7,047,083 B2 5/2006 Gunderson et al. 5,544,139 A 9/1996 Okajima 7,050,855 B2 5/2006 Gunderson et al. 5,554,249 A 1/1996 Shoberg et al. 7,123,013 B2 1/02006 Gray 5,584,873 A 1/1996 Shoberg et al. 7,123,013 B2 1/02006 Gray 5,609,622 A 3/1997 Soukup et al. 7,135,978 B2 1/12006 Gisselberg et al. 5,618,208 A 4/1997 Crouse et al. 7,138,838 B2 1/12006 Gisselberg et al. 5,727,552 A 3/1998 Saad 7,174,219 B2 2/2007 Chitre et al. 5,727,553 A 3/1998 Saad 7,174,220 B1 2/2007 Chitre et al. 5,728,149 A 3/1998<							
S,549,646 A							
5,554,139 A 9/1996 Okajima 7,050,855 B2 5/2006 Zeijlemaker et al.							
S.574,249 A 11/1996 Lindsay 7,113.827 B2 9/2006 Giray							
5,584,873 A 12/1996 Shoberg et al. 7,123,013 B2 10/2006 Gray 5,599,576 A 2/1997 Opolski 7,127,294 B1 10/2006 Wang et al. 5,609,622 A 3/1997 Soukup et al. 7,135,978 B2 11/2006 Gisselberg et al. 5,648,974 A *7/1997 Nelson et al. 607/122 7,138,582 B2 11/2006 Clessar et al. 5,727,553 A 3/1998 Ryan 7,174,219 B2 2/2007 Wahlstrand et al. 5,727,553 A 3/1998 Saad 7,174,220 B1 2/2007 Chitre et al. 5,727,553 A 3/1998 Laske et al. 7,239,916 B2 7/2007 Thompson et al. 5,755,742 A 5/1998 Schuelke et al. 7,239,916 B2 7/2007 Thompson et al. 5,760,341 A 6/1998 Nappholz et al. 7,257,449 B2 82000 5,800,496 A <t< td=""><td></td><td></td><td></td><td>7,113,827</td><td>B2</td><td>9/2006</td><td>Silvestri et al.</td></t<>				7,113,827	B2	9/2006	Silvestri et al.
5,609,622 A 3/1997 Soukup et al. 7,135,978 B2 11/2006 Gisselberg et al. 5,618,208 A 4/1997 Crouse et al. 7,138,582 B2 11/2006 Lessar et al. 5,649,974 A * 7/1997 Nelson et al. 607/122 7,158,837 B2 12/2007 Wahlstrand et al. 5,727,553 A 3/1998 Saad 7,174,219 B2 2/2007 Chitre et al. 5,728,149 A 3/1998 Laske et al. 7,207,678 B2 4/2007 Schulz et al. 5,756,341 A 6/1998 Laske et al. 7,239,916 B2 7/2007 Thompson et al. 5,766,227 A 6/1998 Napholz et al. 7,287,449 B2 8/2007 Bodner 5,810,887 A 9/1998 Swoyer et al. 7,289,851 B2 10/2007 Gunderson et al. 5,824,026 A 10/1998 Nappholz et al. 7,363,090 B2 4/2008 Halperin et al. 5,833,715 A 11/1998 Vachon et al. 7,388,378 B2 6/2008 Gray et al. 5,891,179 A 4/1999 Chien et al. 7,388,378 B2 <td< td=""><td>5,584,873 A</td><td>12/1996</td><td>Shoberg et al.</td><td></td><td></td><td></td><td></td></td<>	5,584,873 A	12/1996	Shoberg et al.				
5,618,208 A 4/1997 Crouse et al. 7,138,582 B2 11/2006 Lessar et al. 5,649,974 A * 7/1997 Nelson et al. 607/122 7,158,837 B2 1/2007 Osypka et al. 5,727,552 A 3/1998 Ryan 7,174,219 B2 2/2007 Val. 5,727,553 A 3/1998 Saad 7,174,219 B1 2/2007 Chitre et al. 5,728,149 A 3/1998 Laske et al. 7,205,768 B2 4/2007 Thompson et al. 5,755,742 A 5/1998 Schuelke et al. 7,239,916 B2 7/2007 Thompson et al. 5,766,227 A 6/1998 Nappholz et al. 7,257,449 B2 8/2007 Bodner 5,800,496 A 9/1998 Swoyer et al. 7,269,898 B1 10/2007 Gunderson et al. 5,817,136 A 10/1998 Nappholz et al. 7,369,898 B1 5/2008 Kroll et al. 5,824,026 A 10/1998 Vachon et al. 7,388,378 B2 6/2008 Gray et al. 5,891,114 A 4/1999 Chien et al. 7,383,318 B2 6/2008 Morgan 5,891,179 A 4/1999 Cross, Jr. et al. 7,535,363 B2 5/2009 Gisselberg et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,610,101 B2 8/2009 Zarembo et al. 5,957,966 A <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
5,649,974 A * 7/1997 Nelson et al. 607/122 7,158,837 B2 1/2007 Osypka et al. 5,727,552 A 3/1998 Ryan 7,174,219 B2 2/2007 Wahlstrand et al. 5,727,553 A 3/1998 Saad 7,174,220 B1 2/2007 Chitre et al. 5,728,149 A 3/1998 Schuelke et al. 7,205,768 B2 4/2007 Schulz et al. 5,755,742 A 5/1998 Schuelke et al. 7,239,916 B2 7/2007 Thompson et al. 5,766,227 A 6/1998 Nappholz et al. 7,257,449 B2 8/2007 Bodner 5,800,496 A 9/1998 Swoyer et al. 7,263,909 B2 4/2007 Gunderson et al. 5,817,136 A 10/1998 Nappholz et al. 7,363,909 B2 4/2007 Gunderson et al. 5,833,715 A 11/1998 Vachon et al. 7,369,898 B1 5/2008 Kroll et al. 5,891,114 A 4/1999 Crie et al. 7,389,148 B1 6/2008 Gray et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,535,363 B2 1/2009 Saloet al. 5,957,970 A 9/1999 Schroeppel et al. 7,571,010 B2 8/2009 <							
5,727,553 A 3/1998 Saad 7,174,220 B1 2/2007 Chitre et al. 5,728,149 A 3/1998 Laske et al. 7,239,916 B2 4/2007 Thompson et al. 5,755,742 A 5/1998 Schuelke et al. 7,239,916 B2 7/2007 Thompson et al. 5,760,341 A 6/1998 Nappholz et al. 7,242,987 B2 7/2007 Holleman et al. 5,766,227 A 6/1998 Nappholz et al. 7,257,449 B2 8/2007 Gunderson et al. 5,810,887 A 9/1998 Accorti, Jr. et al. 7,363,090 B2 4/2008 Halperin et al. 5,817,136 A 10/1998 Nappholz et al. 7,363,090 B2 4/2008 Halperin et al. 5,824,026 A 10/1998 Diaz 7,378,931 B2 5/2008 Cross, Jr. et al. 5,849,031 A 12/1998 Martinez et al. 7,388,378 B2 6/2008 Gray et al. 5,891,114 A 4/1999 Chien et al. 7,453,344 B2 11/2008 Maeda et al. 5,957,966 A 9/1999 Schoepel et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,970 A 9/1999 Schoepel et al. 7,689,291 B2 3/2010 Olkinghorne et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Olkinghorne et al.	5,649,974 A *	7/1997	Nelson et al 607/122				
5,728,149 A 3/1998 Laske et al. 7,205,768 B2 4/2007 Chompson et al. 5,755,742 A 5/1998 Schuelke et al. 7,239,916 B2 7/2007 Thompson et al. 5,760,341 A 6/1998 Nappholz et al. 7,242,987 B2 7/2007 Holleman et al. 5,766,227 A 6/1998 Nappholz et al. 7,257,449 B2 8/2007 Gunderson et al. 5,800,496 A 9/1998 Swoyer et al. 7,363,090 B2 4/2008 Halperin et al. 5,810,887 A 9/1998 Accorti, Jr. et al. 7,369,898 B1 5/2008 Chompson et al. 5,821,136 A 10/1998 Nappholz et al. 7,378,931 B2 5/2000 Odahara et al. 5,833,715 A 11/1998 Vachon et al. 7,389,148 B1 6/2008 Gray et al. 5,891,114 A 4/1999 Chien et al. 7,353,363 B2 6/2008 Morgan 5,891,179 A 4/1999 Chien et al. 7,535,363 B2 5/2009 Gisselberg et al. 5,957,966 A 9/1999 Schroeppel et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,970 A 9/1999 Shoberg et al. 7,689,291 B2 3/2010 Polkinghorne et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Olsen et al.							
5,755,742 A 5/1998 Schuelke et al. 7,239,916 B2 7/2007 Thompson et al. 5,760,341 A 6/1998 Laske et al. 7,242,987 B2 7/2007 Thompson et al. 5,766,227 A 6/1998 Napholz et al. 7,257,449 B2 8/2007 Bodner 5,800,496 A 9/1998 Swoyer et al. 7,289,851 B2 10/2007 Gunderson et al. 5,810,887 A 9/1998 Accorti, Jr. et al. 7,363,090 B2 4/2008 Halperin et al. 5,817,136 A 10/1998 Diaz 7,378,931 B2 5/2008 Odahara et al. 5,824,026 A 10/1998 Diaz 7,378,931 B2 5/2008 Odahara et al. 5,833,715 A 11/1998 Vachon et al. 7,388,148 B1 6/2008 Morgan 5,891,114 A 4/1999 Er et al. 7,453,344 B2 11/2008 Maeda et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,571,010 B2 8/2009 Gisselberg et al. 5,957,970 A 9/1999 Schroeppel et al. 7,610,101 B2 10/2009 Wedan et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2010 Olsen et al. 6,078,840 A 6/2000 Fischer, Sr. 7,912,552 B2 3/2011 Hoegh et al. 6,104,477 A 8/2000 Fischer, Sr. 7,912,552 B2 3/2011 Hoegh et al.							
5,766,227 A 6/1998 Nappholz et al. 7,257,449 B2 8/2007 Gunderson et al. 5,800,496 A 9/1998 Swoyer et al. 7,289,851 B2 10/2007 Gunderson et al. 5,810,887 A 9/1998 Accorti, Jr. et al. 7,363,090 B2 4/2008 Halperin et al. 5,817,136 A 10/1998 Diaz 7,378,931 B2 5/2008 Crollet al. 5,824,026 A 10/1998 Diaz 7,378,931 B2 5/2008 Gray et al. 5,849,031 A 12/1998 Martinez et al. 7,388,148 B1 6/2008 Gray et al. 5,891,114 A 4/1999 Chien et al. 7,535,363 B2 5/2009 Gisselberg et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,970 A 9/1999 Schroeppel et al. 7,630,761 B2 12/2009 Wedan et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Polkinghorne et al. 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 1/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 1/2010 Olsen et al. 6,0522 A 8/2000 Vogel et al. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A							
5,800,496 A 9/1998 Swoyer et al. 5,810,887 A 9/1998 Accorti, Jr. et al. 5,817,136 A 10/1998 Nappholz et al. 5,824,026 A 10/1998 Diaz 5,833,715 A 11/1998 Vachon et al. 5,891,114 A 4/1999 Chien et al. 5,891,179 A 4/1999 Er et al. 5,935,159 A 8/1999 Schroeppel et al. 5,957,966 A 9/1999 Shoberg et al. 5,968,087 A 10/1999 Hess et al. 6,016,447 A 1/2000 Juran et al. 6,078,840 A 6/2000 Stokes 6,003,216 A 7/2000 Fischer, Sr. 6,101,417 A 8/2000 Vogel et al. 6,141,593 A 10/2000 Patag 6,143,013 A 11/2000 Samson et al. 7,289,851 B2 10/2007 Gunderson et al. 7,289,851 B2 4/2008 Halperin et al. 7,369,898 B1 5/2008 Kroll et al. 7,378,931 B2 5/2008 Odahara et al. 7,388,378 B2 6/2008 Morgan 7,453,344 B2 11/2008 Maeda et al. 7,453,344 B2 11/2008 Maeda et al. 7,531,010 B2 8/2009 Zarembo et al. 7,571,010 B2 8/2009 Zarembo et al. 7,610,101 B2 10/2009 Wedan et al. 7,630,761 B2 12/2009 Salo et al. 7,689,291 B2 3/2010 Polkinghorne et al. 7,600,57,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,101,417 A 8/2000 Vogel et al. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Fischer, Sr. 7,912,552 B2 3/2011 Bulkes et al. 6,141,593 A 10/2000 Patag 7,933,662 B2 4/2011 Knapp et al. 7,986,999 B2 7/2011 Wedan et al.							
5,810,887 A 9/1998 Accorti, Jr. et al. 7,363,090 B2 4/2008 Halperin et al. 5,817,136 A 10/1998 Nappholz et al. 7,369,898 B1 5/2008 Kroll et al. 5,824,026 A 10/1998 Diaz 7,378,931 B2 5/2008 Odahara et al. 5,833,715 A 11/1998 Vachon et al. 7,388,378 B2 6/2008 Gray et al. 5,849,031 A 12/1998 Martinez et al. 7,353,344 B2 11/2008 Morgan 5,891,114 A 4/1999 Chien et al. 7,535,363 B2 5/2009 Gisselberg et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,966 A 9/1999 Schroeppel et al. 7,610,101 B2 10/2009 Wedan et al. 5,957,970 A 9/1999 Schroeppel et al. 7,689,291 B2 3/2010 Polkinghorne et al. 5,968,087 A 10/1999 Hess et al. 7,765,005 B2 7/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,871,510 B2 1/2011 Hoegh et al. 6,078,840 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Marshall et al							
5,824,026 A 10/1998 Diaz 7,378,931 B2 5/2008 Gray et al. 0dahara et al. 5,833,715 A 11/1998 Vachon et al. 7,388,378 B2 6/2008 Gray et al. 5,849,031 A 12/1998 Martinez et al. 7,389,148 B1 6/2008 Morgan 5,891,114 A 4/1999 Chien et al. 7,453,344 B2 11/2008 Maeda et al. 5,891,179 A 4/1999 Er et al. 7,535,363 B2 5/2009 Gross, Jr. et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,970 A 9/1999 Schroeppel et al. 7,630,761 B2 10/2009 Wedan et al. 5,968,087 A 10/1999 Hess et al. 7,650,05 B2 7/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,104,477 A 8/2000 Vogel et al. 7,991,255 B2 3/2011 Bulkes et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,104,522 A							
5,833,715 A 11/1998 Vachon et al. 5,849,031 A 12/1998 Martinez et al. 5,891,114 A 4/1999 Chien et al. 5,891,179 A 4/1999 Er et al. 5,935,159 A 8/1999 Cross, Jr. et al. 5,957,966 A 9/1999 Schroeppel et al. 5,957,970 A 9/1999 Shoberg et al. 5,968,087 A 10/1999 Hess et al. 6,016,447 A 1/2000 Juran et al. 6,078,840 A 6/2000 Stokes 7,871,150 B2 1/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 6,083,216 A 7/2000 Fischer, Sr. 6,101,417 A 8/2000 Vogel et al. 6,104,552 A 8/2000 Fieschman et al. 6,143,013 A 11/2000 Samson et al. 6,178,355 B1 1/2001 Williams et al. 7,388,378 B2 6/2008 Gray et al. 7,389,148 B1 6/2008 Morgan 7,389,148 B1 6/2008 Morgan 7,453,344 B2 11/2008 Maeda et al. 7,571,010 B2 8/2009 Gisselberg et al. 7,571,010 B2 10/2009 Wedan et al. 7,630,761 B2 12/2009 Salo et al. 7,689,291 B2 3/2010 Polkinghorne et al. 7,853,332 B2 12/2010 Olsen et al. 7,853,332 B2 12/2010 Olsen et al. 7,877,150 B2 1/2011 Hoegh et al. 7,917,213 B2 3/2011 Przybyszewski 7,917,213 B2 3/2011 Marshall et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 7,991,484 B1 8/2011 Sengupta et al.							
5,849,031 A 12/1998 Martinez et al. 7,389,148 B1 6/2008 Morgan 5,891,114 A 4/1999 Chien et al. 7,453,344 B2 11/2008 Maeda et al. 5,891,179 A 4/1999 Er et al. 7,535,363 B2 5/2009 Gisselberg et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,966 A 9/1999 Schroeppel et al. 7,610,101 B2 10/2009 Wedan et al. 5,957,970 A 9/1999 Schroeppel et al. 7,630,761 B2 12/2009 Salo et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Polkinghorne et al. 6,016,447 A 1/2000 Juran et al. 7,765,005 B2 7/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A <		10/1998	Diaz Vachon et al				
5,891,114 A 4/1999 Chien et al. 7,453,344 B2 11/2008 Maeda et al. 5,891,179 A 4/1999 Er et al. 7,535,363 B2 5/2009 Gisselberg et al. 5,935,159 A 8/1999 Cross, Jr. et al. 7,571,010 B2 8/2009 Zarembo et al. 5,957,966 A 9/1999 Schroeppel et al. 7,610,101 B2 10/2009 Wedan et al. 5,957,970 A 9/1999 Schoberg et al. 7,630,761 B2 12/2009 Salo et al. 5,968,087 A 10/1999 Hess et al. 7,765,005 B2 7/2010 Polkinghorne et al. 6,016,447 A 1/2000 Juran et al. 7,853,332 B2 12/2010 Olsen et al. 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 1/2011 Hoegh et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/200 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.				7,389,148	В1	6/2008	Morgan
5,935,159 A 8/1999 Cross, Jr. et al. 5,957,966 A 9/1999 Schroeppel et al. 5,957,970 A 9/1999 Schroeppel et al. 5,968,087 A 10/1999 Hess et al. 6,016,447 A 1/2000 Juran et al. 6,057,031 A 5/2000 Breme et al. 6,057,031 A 7/2000 Stokes 7,877,150 B2 1/2010 Stevenson 6,083,216 A 7/2000 Fischer, Sr. 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Fischer al. 7,917,213 B2 3/2011 Bulkes et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Knapp et al. 7,986,999 B2 7/2011 Wedan et al. 7,986,999 B2 7/2011 Wedan et al. 7,986,999 B2 7/2011 Wedan et al.							
5,957,966 A 9/1999 Schroeppel et al. 7,610,101 B2 10/2009 Wedan et al. 5,957,970 A 9/1999 Shoberg et al. 7,630,761 B2 12/2009 Salo et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Polkinghorne et al. 6,016,447 A 1/2000 Juran et al. 7,765,005 B2 7/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,106,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.							
5,957,970 A 9/1999 Shoberg et al. 7,630,761 B2 12/2009 Salo et al. 5,968,087 A 10/1999 Hess et al. 7,689,291 B2 3/2010 Polkinghorne et al. 6,016,447 A 1/2000 Juran et al. 7,765,005 B2 7/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,871,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,166,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A							
6,016,447 A 1/2000 Juran et al. 7,765,005 B2 7/2010 Stevenson 6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,106,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.	5,957,970 A	9/1999	Shoberg et al.	, ,			
6,057,031 A 5/2000 Breme et al. 7,853,332 B2 12/2010 Olsen et al. 6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,106,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.							
6,078,840 A 6/2000 Stokes 7,877,150 B2 1/2011 Hoegh et al. 6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,106,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.							
6,083,216 A 7/2000 Fischer, Sr. 7,912,552 B2 3/2011 Przybyszewski 6,101,417 A 8/2000 Vogel et al. 7,917,213 B2 3/2011 Bulkes et al. 6,106,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.	6,078,840 A						
6,106,522 A 8/2000 Fleischman et al. 7,933,662 B2 4/2011 Marshall et al. 6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.	6,083,216 A	7/2000	Fischer, Sr.	7,912,552	B2	3/2011	Przybyszewski
6,141,593 A 10/2000 Patag 7,953,499 B2 5/2011 Knapp et al. 6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.							
6,143,013 A 11/2000 Samson et al. 7,986,999 B2 7/2011 Wedan et al. 6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.							
6,178,355 B1 1/2001 Williams et al. 7,991,484 B1 8/2011 Sengupta et al.							
6,192,280 B1 2/2001 Sommer et al. 8,000,801 B2 8/2011 Stevenson et al.	6,178,355 B1	1/2001	Williams et al.	7,991,484	В1	8/2011	Sengupta et al.
	6,192,280 B1	2/2001	Sommer et al.	8,000,801	B2	8/2011	Stevenson et al.

US 9,254,380 B2 Page 3

(56)	Referer	ices Cited	2005/0272280 A1	12/2005	
U.S.	PATENT	DOCUMENTS	2005/0283167 A1 2006/0009819 A1		Przybyszewski
0.005.504.70	0/2011	W/11	2006/0030774 A1 2006/0041293 A1		Gray et al. Mehdizadeh et al.
8,027,736 B2 8,032,230 B1		Wahlstrand et al. Cox et al.	2006/0041293 A1 2006/0041294 A1	2/2006	
8,046,084 B2		Bodner	2006/0041296 A1	2/2006	Bauer et al.
8,099,177 B2	1/2012	Dahlberg	2006/0089691 A1		Kaplan et al.
8,103,360 B2		Foster	2006/0089695 A1 2006/0089696 A1		Bolea et al. Olsen et al.
8,108,054 B2 8,145,324 B1		Helland Stevenson et al.	2006/0093685 A1		Mower et al.
8,170,688 B2		Wedan et al.	2006/0105066 A1		Teague et al.
8,200,342 B2		Stevenson et al.	2006/0106442 A1 2006/0118758 A1		Richardson et al. Wang et al.
8,214,055 B2 8,244,346 B2		Erickson Foster et al.	2006/0118738 A1 2006/0129043 A1		Ben-Jacob et al.
8,255,055 B2		Ameri	2006/0167536 A1		Nygren et al.
8,306,630 B2		Stubbs et al.	2006/0200218 A1 2006/0229693 A1		Wahlstrand Bauer et al.
8,315,715 B2 8,391,994 B2		Erickson Foster et al.	2006/0229693 A1 2006/0247747 A1		Olsen et al.
8,401,671 B2		Wedan et al.	2006/0247748 A1		Wahlstrand et al.
8,543,209 B2	9/2013	Tyers et al.	2006/0252314 A1		Atalar et al.
8,543,218 B2		Erickson	2006/0253180 A1 2006/0271138 A1		Zarembo et al. MacDonald
8,666,508 B2 8,666,512 B2		Foster et al. Walker et al.	2006/0293737 A1		Krishnan
8,670,840 B2		Wedan et al.	2007/0010702 A1	1/2007	Wang et al.
8,676,351 B2		Foster et al.	2007/0027532 A1 2007/0106332 A1		Wang et al. Denker et al.
8,688,236 B2 2002/0065544 A1	4/2014 5/2002	Foster	2007/0100332 A1 2007/0112398 A1		Stevenson et al.
2002/0003344 AT 2002/0072769 AT		Silvian et al.	2007/0156205 A1	7/2007	Larson et al.
2002/0111664 A1	8/2002	Bartig et al.	2007/0179577 A1		Marshall et al.
2002/0128689 A1		Connelly et al.	2007/0179582 A1 2007/0191914 A1		Marshall et al. Stessman
2002/0144720 A1 2003/0028231 A1	2/2003	Zahorik et al. Partridge et al.	2007/0208383 A1*		Williams 607/2
2003/0050680 A1		Gibson et al.	2007/0255378 A1		Polkinghorne et al.
2003/0063946 A1		Williams et al.	2008/0009905 A1 2008/0033497 A1*		Zeijlemaker Bulkes et al 607/9
2003/0083723 A1 2003/0083726 A1		Wilkinson et al. Zeijlemaker et al.	2008/0033497 A1 2008/0039709 A1		Karmarkar
2003/0083720 AT 2003/0092303 AT		Osypka	2008/0049376 A1	2/2008	Stevenson et al.
2003/0093136 A1	5/2003	Osypka et al.	2008/0051854 A1		Bulkes et al.
2003/0093138 A1		Osypka et al.	2008/0057784 A1 2008/0058902 A1		Zarembo et al. Gray et al.
2003/0139794 A1 2003/0140931 A1		Jenney et al. Zeijlemaker et al.	2008/0119917 A1*		Geistert 607/116
2003/0144705 A1		Funke	2008/0125754 A1		Beer et al.
2003/0144716 A1		Reinke et al.	2008/0129435 A1 2008/0132985 A1	6/2008	Gray Wedan et al.
2003/0144718 A1 2003/0144719 A1		Zeijlemaker Zeijlemaker	2008/0132986 A1		Gray et al.
2003/0144720 A1		Villaseca et al.	2008/0140152 A1	6/2008	Imran et al.
2003/0144721 A1*		Villaseca et al 607/122	2008/0154348 A1 2008/0208290 A1		Atalar et al. Phillips et al.
2003/0204217 A1 2004/0014355 A1*		Greatbatch Osypka et al 439/502	2008/0208290 A1 2008/0243218 A1		Bottomley et al.
2004/0014333 A1 2004/0064161 A1		Gunderson et al.	2008/0262584 A1	10/2008	Bottomley et al.
2004/0064173 A1	4/2004	Hine et al.	2008/0269831 A1		Erickson
2004/0064174 A1		Belden Smits et al.	2009/0005825 A1 2009/0024180 A1		MacDonald Kisker et al.
2004/0088033 A1 2004/0097965 A1*		Gardeski et al 606/129	2009/0024197 A1		Jensen
2004/0122490 A1	6/2004	Reinke et al.	2009/0099440 A1	4/2009	
2004/0153049 A1		Hewitt et al.	2009/0099555 A1 2009/0118610 A1		Viohl et al. Karmarkar et al.
2004/0162600 A1 2004/0172117 A1		Williams Hill et al.	2009/0149920 A1		Li et al.
2004/0193140 A1		Griffin et al.	2009/0149933 A1	6/2009	
2004/0243210 A1		Morgan et al.	2009/0149934 A1 2009/0171421 A1*		Ameri et al 607/63
2004/0267107 A1 2005/0030322 A1		Lessar et al. Gardos	2009/01/1421 A1 2009/0198314 A1		Foster et al.
2005/0070972 A1		Wahlstrand et al.	2009/0204171 A1	8/2009	Ameri
2005/0090886 A1		MacDonald et al.	2009/0210022 A1		Powers
2005/0113676 A1		Weiner et al. Weiner et al.	2009/0270948 A1 2009/0270956 A1		Nghiem et al. Vase et al.
2005/0113873 A1 2005/0113876 A1		Weiner et al.	2009/0281608 A1	11/2009	
2005/0136385 A1		Mann et al.	2010/0010602 A1		Wedan et al.
2005/0177135 A1		Hildebrand et al.	2010/0016935 A1		Strandberg et al.
2005/0182471 A1 2005/0197677 A1	8/2005 9/2005	Wang Stevenson	2010/0103215 A1 2010/0106215 A1		Iriguchi Stubbs et al.
2005/0197677 AT 2005/0222642 AT		Przybyszewski et al.	2010/0100213 A1 2010/0114277 A1*		Zhao A61N 1/056
2005/0222656 A1	10/2005	Wahlstrand et al.			607/116
2005/0222657 A1		Wahlstrand et al.	2010/0125320 A1		Polkinghorne et al.
2005/0222658 A1 2005/0222659 A1		Hoegh et al. Olsen et al.	2010/0137928 A1 2010/0174348 A1		Duncan et al. Bulkes et al.
2005/0222639 AT 2005/0246007 AT		Sommer et al.	2010/01/4348 A1 2010/0174349 A1		Stevenson et al.
2005/0267556 A1		Shuros et al.	2010/0234929 A1		Scheuermann

(56)References Cited OTHER PUBLICATIONS International Search Report and Written Opinion issued in PCT/ U.S. PATENT DOCUMENTS US2008/085518 on Oct. 29, 2009, 15 pages. International Search Report and Written Opinion issued in PCT/ 2010/0249892 A1 9/2010 Bulkes et al. US2010/024062, mailed Sep. 27, 2010. 2010/0292744 A1 11/2010 Hill et al. International Search Report and Written Opinion issued in PCT/ 2010/0331936 A1 12/2010 Perrev et al. US2010/033686 on Aug. 10, 2010, 12 pages. 2011/0060394 A1 3/2011 Poore 2011/0079423 A1 Invitation to Pay Additional Fees and Partial Search Report, dated Zhao et al. 4/2011 2011/0087299 A1 4/2011Aug. 17, 2009, issued in PCT/US2008/085533, 6 pages Ameri 2011/0087302 A1 4/2011 Ameri Invitation to Pay Additional Fees and Partial Search Report, issued in 2011/0160805 A1 6/2011 Erbstoeszer et al. PCT/US2010/024062, mailed May 7, 2010. 2011/0160816 A1 6/2011 Stubbs et al. International Search Report and Written Opinion issued in PCT/ 2011/0160817 A1 6/2011 Foster et al. US2010/048638, mailed Nov. 12, 2010, 12 pages. 2011/0160818 A1 6/2011 Struve 2011/0160828 A1 6/2011 Foster et al. International Search Report and Written Opinion issued in PCT/ 2011/0160829 A1 6/2011 US2009/032838, mailed May 4, 2009, 14 pages. Foster et al. 2011/0208280 A1 8/2011 Li et al. International Search Report and Written Opinion issued in PCT/ 2011/0218422 A1 9/2011 Atalar et al US2010/055130, mailed Mar. 10, 2011, 11 pages. 2011/0238146 A1 9/2011 Wedan et al. International Search Report and Written Opinion issued in PCT/ 2011/0288403 A1 11/2011 Kondabatni et al. US2010/055653, mailed Feb. 1, 2011, 14 pages 2012/0016451 A1 1/2012 Struve et al. Partial International Search Report issued in PCT/US2013/013432, 2012/0022356 A1 1/2012 Olsen et al. mailed Jul. 17, 2013, 6 pages. 2012/0035698 A1 2/2012 Johnson et al. 2012/0053662 A1 3/2012 Partial International Search Report issued in PCT/US2013/037432, Foster et al. 2012/0109270 A1 5/2012 mailed Jul. 17, 2013, 6 pages. Foster Third Party Submission Under 37 CFR 1.290 filed in U.S. Appl. No. 2012/0143273 A1 6/2012Stubbs et al. 2012/0161901 A1 6/2012 Stevenson et al. 14/056,746 on May 20, 2014, 13 pages. 2012/0179233 A1 7/2012 Wedan et al. International Search Report and Written Opinion issued in PCT/ 2012/0253340 A1 10/2012 Stevenson et al. US2013/065517, mailed Dec. 20, 2013, 11 pgs. 2012/0271394 A1 10/2012 Foster et al. "High Voltage Engineering and Testing, 2nd Edition", edited by 2013/0116764 A1 5/2013 Walker et al. Hugh M. Ryan, Institution of Engineering and Technology, 2001, 15 2013/0158641 A1 6/2013 Foster et al. pages. 2013/0190849 A1 7/2013 Perrey et al. Avalanche Breakdown, Wikipedia Article, captured Apr. 6, 2010, 2013/0190850 A1 7/2013 Wedan et al. [http://en.wikipedia.org/wiki/Avalanche_breakdown]. 2013/0282093 A1 10/2013 Walker et al. Basso, Christophe, "SPICE Model Simulates Spark-Gap Arrestor", 2013/0325093 A1 12/2013 Foster Electronics Design, Strategy, and News (EDN), Jul. 3, 1997, 4 pages. 2014/0067030 A1 3/2014 Walker et al. 2014/0114383 A1 4/2014 Foster et al. Citel Inc., Data Sheet, BH Series 2 Electrode Miniature Gas Dis-2014/0155972 A1 6/2014 Foster et al. charge Tube Surge Arrester—8mm, May 14, 2009, 2 pages 2014/0324139 A1 10/2014 Foster et al. File History for U.S. Appl. No. 11/015,807, filed Dec. 17, 2004 to

FOREIGN PATENT DOCUMENTS

CN	101039619 A	9/2007
EP	0897997 B1	2/2003
EP	1594564 A1	11/2005
EP	1852810 B1	11/2007
JP	2004141679 A	5/2004
JP	2005501673 A	1/2005
JP	2005515852 A	6/2005
JP	2005515854 A	6/2005
WO	WO9606655 A1	3/1996
WO	WO03063953 A2	8/2003
WO	WO03089045 A2	10/2003
WO	WO2004073791 A1	9/2004
WO	WO03063946 A2	4/2005
WO	WO2005030322 A1	4/2005
WO	WO2006105066 A2	3/2006
WO	WO2006093685 A1	9/2006
WO	WO2007047966 A2	4/2007
WO	WO2007089986 A1	8/2007
WO	WO2007118194 A2	10/2007
WO	WO2008051122 A1	5/2008
WO	WO2009137186 A1	11/2009
WO	WO2010078552 A1	7/2010

Cooke, Daniel J. et al. Hayes, David L., Char

Hayes, David L., Chapter 4, "Generator and Lead Selection" from book entitled "Cardiac Pacing and Defibrillation a Clinical Approach", John Wiley & Sons, (c) 2000 Mayo Foundation, p. 129-157.

International Search Report and Written Opinion issued in PCT/US2009/056843, mailed Dec. 29, 2009, 13 pages.

International Search Report and Written Opinion issued in PCT/US2010/048620, mailed Apr. 5, 2011, 10 pages.

International Search Report and Written Opinion issued in PCT/US2010/053223, mailed Dec. 27, 2010, 11 pages.

International Search Report and Written Opinion issued in PCT/US2011/052541, dated Mar. 9, 2012, 22 pages.

International Search Report and Written Opinion issued in PCT/US2013/037432, mailed Nov. 19, 2013, 17 pages.

International Search Report and Written Opinion issued in PCT/

US2013/057732, mailed Dec. 13, 2013, 11 pages.

Partial International Search Report issued in PCT/US2011/052541, mailed Dec. 6, 2011, 4 pages.

Static Spark Gap Analysis, captured Dec. 24, 2002, [http://www.richieburnett.co.uk/static.html].

^{*} cited by examiner







FIG. 1







MRI COMPATIBLE TACHYCARDIA LEAD

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to Provisional Application No. 61/252,915, filed Oct. 19, 2009, which is herein incorporated by reference in its entirety.

TECHNICAL FIELD

The present invention relates to implantable medical devices. More particularly, the present invention relates to MRI-compatible tachycardia lead constructions.

BACKGROUND

Magnetic resonance imaging (MRI) is a non-invasive imaging procedure that utilizes nuclear magnetic resonance techniques to render images within a patient's body. Typically, MRI systems employ the use of a magnetic coil having a magnetic field strength of between about 0.2 to 3 Teslas. During the procedure, the body tissue is briefly exposed to RF pulses of electromagnetic energy in a plane perpendicular to the magnetic field. The resultant electromagnetic energy from these pulses can be used to image the body tissue by measuring the relaxation properties of the excited atomic nuclei in the tissue.

During imaging, the electromagnetic radiation produced by the MRI system may be picked up by implantable device leads used in implantable medical devices such as pacemakers or cardiac defibrillators. This energy may be transferred through the lead to the electrode in contact with the tissue, which may lead to elevated temperatures at the point of contact. The degree of tissue heating is typically related to factors such as the length of the lead, the conductivity or impedance of the lead, and the surface area of the lead electrodes. Exposure to a magnetic field may also induce an undesired voltage on the lead.

SUMMARY

The present invention relates to a medical device lead including a proximal connector configured to couple the lead 45 to a pulse generator, an insulative lead body extending distally from the proximal connector, a conductor assembly extending distally from the proximal connector within the lead body. The conductor assembly includes a conductor having a proximal end electrically coupled to the connector and a distal end 50 electrically coupled to a defibrillation coil. A first portion of the defibrillation coil is exposed at an outer surface of the medical device lead and a second portion of the defibrillation coil is insulated at the outer surface of the medical device

In another aspect, a medical device lead includes a first connector configured to couple the lead to a pulse generator, an insulative lead body extending distally from the first connector, and a first conductor extending distally from the first connector within the lead body and having a proximal end 60 electrically coupled to the first connector. A first defibrillation coil is exposed at an outer surface of the medical device lead, and a first high impedance coil is connected between the first conductor and the first defibrillation coil. The first high impedance coil is insulated at the outer surface of the medical 65 device lead and has an impedance greater than the first conductor.

2

In a further aspect, a medical device lead includes one or more proximal connectors each configured to couple to a pulse generator, an insulative lead body extending distally from the one or more proximal connectors, and one or more conductors each extending distally from and electrically connected to one of the one or more proximal connectors. One or more defibrillation coils are each connected to a distal end of one of the one or more conductors. A first portion of each defibrillation coil is exposed at an outer surface of the medical device lead and a second portion of each defibrillation coil is insulated at the outer surface of the medical device lead.

While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic view of a cardiac rhythm management (CRM) system including a pulse generator and a lead implanted in a patient's heart according to an embodiment of the present invention.

FIG. 2 is a cross-sectional view of a distal portion of a lead according to an embodiment of the present invention including a defibrillation coil that is partially insulated.

FIG. **3**A is a cross-sectional view of a distal portion of a lead according to another embodiment of the present invention including two defibrillation coils that are each partially insulated

FIG. 3B is a cross-sectional view of a portion of the lead proximal to the distal portion of the lead shown in FIG. 3A.

FIG. 4 is a schematic view of an implantable medical device including a lead having a plurality of high impedance coils in series with a conductive cable that extends through the lead body according to a further embodiment of the present invention.

While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION

FIG. 1 is a schematic view of a cardiac rhythm management (CRM) system 10 according to an embodiment of the present invention. As shown in FIG. 1, the CRM system 10 includes a pulse generator 12 coupled to a plurality of leads 55 14, 16 deployed in a patient's heart 18. As further shown in FIG. 1, the heart 18 includes a right atrium 24 and a right ventricle 26 separated by a tricuspid valve 28. During normal operation of the heart 18, deoxygenated blood is fed into the right atrium 24 through the superior vena cava 30 and the inferior vena cava 32. The major veins supplying blood to the superior vena cava 30 include the right and left axillary veins 34 and 36, which flow into the right and left subclavian veins 38 and 40. The right and left external jugular 42 and 44, along with the right and left internal jugular 46 and 48, join the right and left subclavian veins 38 and 40 to form the right and left brachiocephalic veins 50 and 52, which in turn combine to flow into the superior vena cava 30.

The leads 14, 16 operate to convey electrical signals and stimuli between the heart 18 and the pulse generator 12. In the illustrated embodiment, the lead 14 is implanted in the right ventricle 26, and the lead 16 is implanted in the right atrium 24. In other embodiments, the CRM system 10 may include additional leads, e.g., a lead extending into a coronary vein for stimulating the left ventricle in a bi-ventricular pacing or cardiac resynchronization therapy system. As shown, the leads 14, 16 enter the vascular system through a vascular entry site 54 formed in the wall of the left subclavian vein 40, extend through the left brachiocephalic vein 52 and the superior vena cava 30, and are implanted in the right ventricle 26 and right atrium 24, respectively. In other embodiments of the present invention, the leads 14, 16 may enter the vascular system through the right subclavian vein 38, the left axillary vein 36, the left external jugular 44, the left internal jugular 48, or the left brachiocephalic vein 52.

The pulse generator 12 is typically implanted subcutaneously within an implantation location or pocket in the 20 patient's chest or abdomen. The pulse generator 12 may be any implantable medical device known in the art or later developed, for delivering an electrical therapeutic stimulus to the patient. In various embodiments, the pulse generator 12 is a pacemaker, an implantable cardiac defibrillator, and/or 25 includes both pacing and defibrillation capabilities. The portion of the leads 14, 16 extending from the pulse generator 12 to the vascular entry site 54 are also located subcutaneously or submuscularly. The leads 14, 16 are each connected to the pulse generator 12 via proximal connectors. Any excess lead 30 length, i.e., length beyond that needed to reach from the pulse generator 12 location to the desired intracardiac implantation site, is generally coiled up in the subcutaneous pocket near the pulse generator 12.

FIG. 2 is a cross-sectional view of the lead 14 according to 35 an embodiment of the present invention. The lead 14 includes a defibrillation coil 60, and pacing or sensing electrodes 62and 64. The defibrillation coil 60 may be used to deliver a high voltage therapy signal to a portion of the heart 18. The pacing or sensing electrodes 62 and 64 may be used for pacing, 40 sensing, or both. In the embodiment shown, the electrode 62 is a ring electrode, and the electrode 64 includes a fixation helix. In some embodiments, the electrodes 62 and 64 include platinum or titanium coated with a combination of iridium oxide (IrOx), titanium/nickel (Ti/Ni), black platinum (Pt 45 black), or tantalum oxide (TaO). The defibrillation coil 60 and the pacing or sensing electrodes 62 and 64 are located near a distal end portion of the lead 14. In alternative embodiments, the defibrillation and pacing or sensing electrodes are located elsewhere on the lead 14. The lead 14 may also alternatively 50 include fewer or more electrodes.

The electrode 62 is coupled to a first conductive coil 70, and the electrode 64 is coupled to a second conductive coil 72. The second conductive coil 72 is surrounded by an insulative layer 80 to insulate the conductive coil 72 from other ele- 55 ments of the lead 14. In some embodiments, the insulative layer 80 extends from the proximal end to the distal end of the lead 14. An insulative layer 82 is also formed around the first conductor 70. In some embodiments, the insulative layer 82 extends from the proximal end of the lead 14 to the electrode 60 **62**. With this arrangement, the electrode **62** is exposed at the outer surface of the lead 14 to allow contact with adjacent tissue. The insulative layers 80 and 82 may be comprised of, for example, silicone material, Teflon, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), 65 ethylene tetrafluoroethylene (ETFE), or another suitable nonconductive material. The electrodes 62 and 64, the conductive

4

coils 70 and 72, and the insulative layers 80 and 82 combine to form the low voltage pacing/sensing portion 85 of the lead 14

The first conductive coil 70 and the second conductive coil 72 extend through the lead 14 and are adapted for connection to the pulse generator 12 at the proximal end of the lead 14. In some embodiments, the first conductive coil 70 and the second conductive coil 72 are each coupled to a proximal connector at the proximal end of the lead 14. The connectors at the proximal end of the lead 14 are sized and shaped to interface with a connector block or other component of the pulse generator 12. The signals carried by the first conductive coil 70 and the second conductive coil 72 may be independently controlled by the pulse generator 12 such that different signals may be delivered to and/or received from the electrodes 62 and 64.

The defibrillation coil 60 is coupled to a conductive cable 90, which extends through the lead 14 and is adapted for connection to the pulse generator 12 at the proximal end of the lead 14. The conductive cable 90 may extend through the lead 14 in a lumen parallel to the conductive coils 70 and 72. The conductive cable 90 is surrounded by an insulating layer 92 at an exterior surface of the lead 14. In some embodiments, the conductive cable 90 is coupled to a proximal connector at the proximal end of the lead 14 that is sized and shaped to interface with a connector block or other component of the pulse generator 12. The conductive cable 90 delivers a high voltage defibrillation signal from the pulse generator 12 to the defibrillation coil 60. The lead 14 is arranged in the heart 18 such that the signal delivered by the defibrillation coil 60 depolarizes a critical mass of the heart muscle, terminates an arrhythmia, and allows normal sinus rhythm to be reestablished.

In a magnetic resonance imaging (MRI) environment, the radio frequency (RF) fields can induce a current in the conductive elements of the lead 14. This current may then be dissipated at the point of contact between the lead electrodes and adjacent tissue, resulting in elevated temperatures in the tissue. To reduce the RF current that is transmitted to the defibrillation coil 60 by the conductive cable 90, a length L of the defibrillation coil 60 is insulated at the exterior surface of the lead 14 by insulating layer 92. The insulated length L of the defibrillation coil 60 acts as an RF filter between the conductive cable 90 and the exposed portion of the defibrillation coil 60. More specifically, the inductance of a coil is directly proportional to the square of the radius of the coil. Thus, the inductance of the defibrillation coil 60 is large due to its large diameter. In some embodiments, the outside diameter of the defibrillation coil 60 is in the range of about 0.08 to 0.12 inch (about 2.0 to 3.0 mm). Consequently, the insulated length L of the defibrillation coil 60 reduces the amount of MRI-induced energy that is transmitted to the defibrillation coil 60 via the conductive cable 90. In some embodiments, the proximal and distal ends of the exposed portion of the defibrillation coil 60 are short circuited with an optional low impedance connection 94 (shown in phantom) to evenly distribute the high voltage signal across the exposed portion.

The inductance of a coil is also directly proportional to the square of the number of turns in the coil. Thus, in order to further reduce the amount of energy that is transmitted to the defibrillation coil 60, the turns of the defibrillation coil 60 may be tightly wound to maximize the inductance of the coil. Also, a unifilar coil may be used to minimize the space between adjacent turns and maximize the number of turns in the defibrillation coil 60. In some embodiments, filar of the defibrillation coil 60 has a diameter in the range of about 0.005 to 0.012 inch (about 0.125 mm to 0.305 mm).

In one exemplary implementation, the defibrillation coil **60** has a length of about 80 mm and an outside diameter of about 2.5 mm. The defibrillation coil **60** is a unifilar coil having a filar diameter of about 0.10 mm. The length L of the defibrillation coil **60** that is insulated is about 30 mm, and the distance separating the defibrillation coil **60** from the ring electrode **62** is about 12.5 mm. A lead **14** having this arrangement showed a reduction in heating of about 5-10° C. at the insulation-exposed coil interface of the defibrillation coil **60** compared to leads including a defibrillation coil **60** without a proximal 10 insulated portion.

In alternative embodiments in which the defibrillation coil 60 is multifilar and/or in which the turns of the defibrillation coil 60 are not tightly wound, the length L of the defibrillation coil 60 that is insulated may be increased to increase the 15 impedance of the insulated length L.

Thus, the length L, the number of turns, and the number of filars in the insulated section of the defibrillation coil $\bf 60$ are selected to provide a reduction in MRI-induced energy in the exposed (i.e., non-insulated) section of the defibrillation coil $\bf 20$ $\bf 60$ while minimizing the increase in resistance prior to the exposed portion of the defibrillation coil $\bf 60$. In some embodiments, these parameters are selected to provide a total DC resistance in the conductive cable $\bf 90$ and the insulated length L of less than about $\bf 5$ $\bf \Omega$.

FIG. 3A is a cross-sectional view of a distal portion of a lead 100 according to another embodiment of the present invention. FIG. 3B is a cross-sectional view of a portion of the lead 100 proximal to the distal portion of the lead shown in FIG. 3A. The lead 100 is another exemplary configuration 30 that may be employed as lead 14 in FIG. 1. As is shown, the proximal end of the distal portion of lead 100 shown in FIG. 3A is electrically coupled to the distal end of the proximal portion of lead 100 shown in FIG. 3B.

The lead 100 includes a distal defibrillation coil 102, a 35 proximal defibrillation coil 104, a ring electrode 106, and a tip electrode 108. The distal defibrillation coil 102 and proximal defibrillation coil 104 may be used to deliver a high voltage therapy signal to different portions of the heart 18. The ring electrode 106 and/or the tip electrode 108 may be used for 40 pacing, sensing, or both. In the embodiment shown, the ring electrode 106 is common with the distal defibrillation coil 102 and the tip electrode 108 includes a fixation helix. By making the ring electrode 106 common with the distal defibrillation coil 102, the diameter of the lead 100 is mini- 45 mized. When shock therapy is not being delivered through the defibrillation coils 102 and 104, a pacing voltage may be generated between the electrodes 106 and 108. In alternative embodiments, the pacing or sensing electrodes are located elsewhere on the lead 100. The lead 100 may also alterna- 50 tively include fewer or more electrodes.

The tip electrode 108 is coupled to a conductive coil 110, which is surrounded by an insulative layer 112 to insulate the conductive coil 110 from other elements of the lead 100. In some embodiments, the insulative layer 112 extends from the 55 proximal end to the distal end of the lead 100. The insulative layer 112 may be comprised of, for example, silicone material, Teflon, expanded polytetrafluoroethylene (ePTFE), polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), or another suitable non-conductive material. The 60 electrodes 106 and 108, the conductive coil 110, and the insulative layer 112 combine to form the low voltage pacing/sensing portion 114 of the lead 100.

The conductive coil 110 extends through the lead 100 and is adapted for connection to the pulse generator 12 at the 65 proximal end of the lead 100. In some embodiments, the conductive coil 110 is coupled to a proximal connector at the

6

proximal end of the lead 100. The connectors at the proximal end of the lead 100 are sized and shaped to interface with a connector block or other component of the pulse generator 12

The distal defibrillation coil 102 is coupled to a conductive cable 120, and the proximal defibrillation coil 104 is coupled to a conductive cable 122. The conductive cables 120 and 122 extend through the lead 100 and are adapted for connection to the pulse generator 12 at the proximal end of the lead 100. In some embodiments, the conductive cables 120 and 122 may extend through the lead 100 in separate lumens parallel to the conductive coil 110. The conductive cable 120 is surrounded by an insulating layer 112 at an exterior surface of the lead 100. In some embodiments, the conductive cables 120 and 122 are each coupled to a proximal connector at the proximal end of the lead 100 that is sized and shaped to interface with a connector block or other component of the pulse generator 12. The conductive cables 120 and 122 delivers a high voltage defibrillation signal from the pulse generator 12 to the defibrillation coils 102 and 104, respectively.

To reduce the RF current that is transmitted to the defibrillation coils 102, 104 by the conductive cables 120 and 122, a length L₁ of the defibrillation coil 102 and a length L₂ of the defibrillation coil 104 are insulated at the exterior surface of the lead 100 by insulating layer 124. The insulated lengths L₁, L₂ act as RF filters between the conductive cables 120, 122 and the exposed portions of the defibrillation coils 102, 104, respectively. Consequently, the insulated lengths L₁, L₂ reduce the amount of MRI-induced energy that is transmitted to the defibrillation coils 102, 104, respectively. In addition, the portion of the defibrillation coil 102 that is insulated between the ring electrode 106 and the exposed portion of the defibrillation coil 102 may provide a further reduction in the amount of MRI-induced energy that is transmitted to the defibrillation coil 102 and/or the ring electrode 106.

The inductance of a coil is also directly proportional to the square of the number of turns in the coil. Thus, in order to further reduce the amount of energy that is transmitted to the defibrillation coils 102, 104, the turns of the defibrillation coils 102, 104 may be tightly wound to maximize the inductance of the coil. Also, unifilar coils may be used to minimize the space between adjacent turns and maximize the number of turns in the defibrillation coils 102, 104. In alternative embodiments in which the defibrillation coil is multifilar and/or in which the turns of the defibrillation coil are not tightly wound, the lengths L_1 , L_2 of the defibrillation coils 102, 104 that are insulated may be increased to increase the impedance of the insulated lengths L_1 , L_2 .

Thus, the lengths L_1 , L_2 , the number of turns, and the number of filars in the insulated section of the defibrillation coils 102, 104 are selected to provide a reduction in MRI-induced energy in the exposed (i.e., non-insulated) sections of the defibrillation coils while minimizing the increase in resistance prior to the exposed portion of the defibrillation coils 102, 104. In some embodiments, these parameters are selected to provide a total DC resistance of the conductive cable 120 and the insulated length L_1 of less than about 5 Ω , and a total DC resistance of the conductive cable 122 and the insulated length L_2 of less than about 5 Ω .

In an alternative embodiment, the diameters of the exposed portions of the defibrillation coils 102, 104 may be increased to make the outer diameter of the defibrillation coils 102, 104 substantially equal to the outer diameter of the insulating layer 124. As a result, the lead 100 has a uniform outer diameter along its length. In one example implementation, a second, larger coil having an outer diameter substantially equal to the outer diameter of the insulating layer 124 is

arranged around and in contact with the exposed portion of each of the defibrillation coils 102, 104. In another example implementation, the thickness of the insulating layer 112 is increased under the exposed portion of each of the defibrillation coils 102, 104 to increase the outer diameter of the 5 defibrillation coils 102, 104 to be substantially equal to the outer diameter of the insulating layer 124.

FIG. 4 is a schematic view of an implantable medical device 150 including a pulse generator 12 and a lead 152 according to a further embodiment of the present invention. 10 The lead 152 includes features that may be incorporated into either lead 14 or lead 100 described above. The lead 152 includes a defibrillation coil 154, a ring electrode 156 and a tip electrode 158. The defibrillation coil 154, the ring electrode 156, and the tip electrode 158 are located near a distal 15 end portion of the lead 152. The lead 152 may also alternatively include fewer or more electrodes.

The defibrillation coil 154 is coupled to a conductive cable 160, which extends through the lead 150 and is adapted for connection to the pulse generator 12 at the proximal end of the 20 lead 150. While not shown in FIG. 4, electrodes 156 and 158 are also electrically coupled to the pulse generator, such as via conductive coils as shown in FIGS. 2, 3A, and 3B, for example. In some embodiments, the conductive cable 160 is coupled to a proximal connector at the proximal end of the 25 lead 14 that is sized and shaped to interface with a connector block 162 or other component of the pulse generator 12. The conductive cable 160 delivers a high voltage defibrillation signal from the pulse generator 12 to the defibrillation coil **154**. The lead **152** is arranged in the heart **18** such that the 30 signal delivered by the defibrillation coil 154 depolarizes a critical mass of the heart muscle, terminates an arrhythmia, and allows normal sinus rhythm to be reestablished.

As in the embodiments described above, a length L of the defibrillation coil 154 is insulated to increase the inductance 35 between the conductive cable 160 and the exposed portion of the defibrillation coil 154. In the embodiment shown in FIG. 4, high impedance coils 170 are coupled in series with the conductive cable 160. The high impedance coils 170 provide an additional reduction in the amount of MRI-induced energy 40 that is transmitted to the defibrillation coil 154. In addition, a high impedance coil 170 may be connected in series with the conductive cable 160 proximate the pulse generator 12 to reduce heating of the pulse generator housing. The high impedance coils 170 may be arranged periodically along the 45 length of the conductive cable 160. In some embodiments, the length of the conductive cable 160 between adjacent high impedance coils 170 is less than one quarter wavelength ($\lambda/4$) of a signal carried by the conductive cable 160. This minimizes the energy picked up by the conductive cable 160 in an 50 MRI environment.

In summary, embodiments of the present invention relate to a medical device lead including a proximal connector configured to couple the lead to a pulse generator, an insulative lead body extending distally from the proximal connector, a con- 55 defibrillation coil is unifilar. ductor assembly extending distally from the proximal connector within the lead body. The conductor assembly includes a conductor having a proximal end electrically coupled to the connector and a distal end electrically coupled to a defibrillation coil. A first portion of the defibrillation coil is exposed 60 at an outer surface of the medical device lead and a second portion of the defibrillation coil is insulated at the outer surface of the medical device lead. The insulated portion of the defibrillation coil, which has a high impedance due to its relatively large diameter, acts as a filter for the radio frequency (RF) energy that is picked up by the conductor in a magnetic resonance imaging (MRI) environment. This

8

reduces the transfer of RF energy to the defibrillation electrode, thereby decreasing the amount of heating of the tissue around the electrode.

Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.

We claim:

- 1. A medical device lead comprising:
- a first connector configured to couple the lead to a pulse generator;
- an insulative lead body extending distally from the first connector:
- a first cable conductor extending distally from the first connector within the lead body and having a first segment having a proximal end coupled to the first connector, a second segment, and a third segment, the first cable conductor extending in a straight configuration within the lead body along each of the first, second, and third segments;
- a first defibrillation coil exposed at an outer surface of the medical device lead, the first defibrillation coil having a proximal end that is electrically connected to a distal end of the third segment of the first cable conductor; and
- a first high impedance coil connected in series to a second high impedance coil, a distal end of the first segment of the first cable conductor coupled to a proximal end of the first high impedance coil, a proximal end of the second segment of the first cable conductor coupled to a distal end of the first high impedance coil, a distal end of the second segment of the first cable conductor coupled to a proximal end of the second high impedance coil, and a distal end of the second high impedance coil coupled to a proximal end of the third segment of the first cable conductor, wherein each of the first segment of the first cable conductor, the first high impedance coil, the second segment of the first cable conductor, the second high impedance coil, the third segment of the first cable conductor, and the first defibrillation coil are respectively electrically connected to one another in series, wherein each of the first, second, and third segments of the first cable conductor has a respective length that is less than one quarter of a wavelength of a signal carried by the first cable conductor and each of the first high impedance coil and the second high impedance coil is insulated at the outer surface of the medical device lead and has an impedance greater than the first cable conductor.
- 2. The medical device lead of claim 1, wherein the first defibrillation coil is unifilar.
- 3. The medical device lead of claim 2, wherein opposing ends of the first defibrillation coil are short circuited.
- **4**. The medical device lead of claim **3**, wherein the insulative lead body comprises a layer of insulation that extends over a portion of the first defibrillation coil and terminates proximally of the outer surface to expose the first defibrillation coil distally of the layer of insulation.
- 5. The medical device lead of claim 4, wherein the first high impedance coil and the first cable conductor have a total DC resistance of less than about 5 Ω .
- 6. The medical device lead of claim 5, and further compris-

- a second connector configured to couple the lead to the pulse generator;
- a second cable conductor having a proximal end electrically coupled to the second connector;
- a second defibrillation coil exposed at an outer surface of 5 the medical device lead; and
- a third high impedance coil connected between the second conductor and the second defibrillation coil, wherein the third high impedance coil is insulated at the outer surface of the medical device lead and has an impedance greater 10 than the second conductor.

* * * * *